Every Form 4 that DiaMedica Therapeutics Inc. (DMAC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DMAC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DMAC filings page.
Pauls Dietrich John reported acquisition or exercise transactions in this Form 4 filing.
DiaMedica Therapeutics Inc. reported that President & CEO Dietrich John Pauls received a grant of 60,200 restricted stock units (RSUs) of voting common shares at no stated per-share cost. These RSUs vest in four equal annual installments on the first through fourth anniversaries of the grant date, contingent on continued service. Following this award, Pauls holds 128,791 voting common shares, including 1,749 shares issuable upon settlement of deferred share units granted under the company’s Deferred Share Unit Plan.
DiaMedica Therapeutics Inc. director Randall Michael Giuffre received a grant of stock options representing 40,412 Voting Common Shares. The options have an exercise price of $5.84 per share, expire on June 1, 2036, and are scheduled to vest in four equal quarterly installments.
DiaMedica Therapeutics Inc. director Richard Kuntz reported a grant of stock options. He received options covering 40,412 Voting Common Shares at an exercise price of $5.84 per share, expiring on June 1, 2036. These options are scheduled to vest in four equal quarterly installments, and following this grant he holds 40,412 derivative securities directly.
DiaMedica Therapeutics Inc. director Daniel J. O'Connor received a grant of stock options to acquire 40,412 voting common shares. The options have an exercise price of $5.84 per share, expire on June 1, 2036, and are scheduled to vest in four equal quarterly installments. Following this grant, he holds options for 40,412 shares directly.
DiaMedica Therapeutics Inc. director Tanya Lewis received a grant of stock options as part of her compensation. She was awarded 40,412 stock options with a conversion or exercise price of $5.84 per share, giving her the right to buy Voting Common Shares at that price.
The options are scheduled to vest in four equal quarterly installments and will expire on June 1, 2036. Following this grant, she holds 40,412 derivative securities related to this award, indicating a routine, compensation-related acquisition rather than an open-market purchase or sale.
DiaMedica Therapeutics Inc. director Charles Pauling Semba received a new stock option grant. He was awarded options for 40,412 shares of Voting Common Shares at an exercise price of $5.84 per share. These options are scheduled to vest in four equal quarterly installments and expire on June 1, 2036.
DiaMedica Therapeutics Inc. director James T. Parsons received a stock option grant reported on a Form 4. He was awarded options to purchase 51,189 Voting Common Shares at an exercise price of $5.84 per share, expiring on June 1, 2036.
The grant is classified as a compensation-related award, not an open-market purchase, and is held directly. According to the disclosure, the options are scheduled to vest in four substantially equal quarterly installments, meaning his ability to exercise them will phase in over time.
DiaMedica Therapeutics Inc. President & CEO Dietrich John Pauls received a grant of stock options covering 380,000 Voting Common Shares. The options have an exercise price of $5.84 per share and expire on June 1, 2036.
The award is compensation-related rather than an open-market trade. It is scheduled to vest 25% on the one-year anniversary of the grant date, with the remaining options vesting in twelve equal quarterly installments. Following this grant, he holds 380,000 stock options directly.
DiaMedica Therapeutics Inc. reported that its CFO and Secretary, Kellen Scott, received a grant of stock options classified as a derivative security. The award covers 162,000 stock options, each giving the right to buy one voting common share at an exercise price of $5.84 per share.
The options were granted as compensation, not as an open-market purchase, and are held directly. They are scheduled to vest 25% on the one-year anniversary of the grant date, with the remaining options vesting in twelve equal quarterly installments, and they expire on June 1, 2036.
DiaMedica Therapeutics Inc. reported that its Chief Medical Officer, Julie Krop, received a new stock option grant. The award covers 67,500 stock options with an exercise price of $5.84 per share and expires on June 1, 2036.
The options relate to 67,500 voting common shares and were granted at no upfront cost as a compensation award. According to the vesting terms, 25% of the options are scheduled to vest on the one-year anniversary of the grant date, with the remaining options vesting in twelve equal quarterly installments thereafter.
DiaMedica Therapeutics Inc. director Semba Charles Pauling reported an equity-based compensation grant. On January 2, 2026, he acquired 3,355 shares of common stock at $8.42 per share, bringing his directly held stake to 47,963 shares.
The footnote explains that these shares are issuable upon settlement of restricted stock units granted under the company’s Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees totaling $28,250. The restricted stock units are scheduled to vest in four nearly equal installments on March 31, June 30, September 30, and December 31, 2026, meaning the director earns the related shares over the course of the year as service-based conditions are met.
DiaMedica Therapeutics Inc. (DMAC) director reports stock option exercise. A company director exercised a stock option to acquire 12,000 common shares of DiaMedica on 11/21/2025 at an exercise price of $2.20 per share, with the price shown after converting the original CAD$ exercise price to US$ on the transaction date. Following this transaction, the director directly owns 87,854 common shares of DiaMedica. The derivative position reported was a stock option (right to buy) for 12,000 shares that was fully vested and, after the exercise, the number of derivative securities beneficially owned is reported as 0.
DiaMedica Therapeutics (DMAC) reported a Form 4 for its Chief Marketing Officer showing a grant of stock options to purchase 450,000 shares at an exercise price of $4.58 per share on 08/11/2025. The options expire on 08/10/2035 and were reported as directly owned following the transaction.
The filing states a time-based vesting schedule: 112,500 options vest on the one-year anniversary of the grant date, and the remaining 337,500 vest in twelve equal quarterly installments starting three months after that one-year mark, conditioned on continued service.